Treatment for Transthyretin Amyloid Cardiomyopathy Receives FDA Approval – Drug for nerve pain boosts high for opioid abusers. (866) 348-2889
Officials with the FDA have approved tafamidis meglumine and tafamidis (Vyndaqel and Vyndamax, Pfizer) for transthyretin amyloid cardiomyopathy (ATTR-CM), a rare and life-threatening disease that is defined by restrictive cardiomyopathy and progressive heart failure, according to a press release.
Both treatments, which are oral formulations of transthyretin stabilizer tafamidis, are approved to treat either wild-type or hereditary ATTR-CM. There are approximately 100,000 individuals in the United States with ATTR-CM, of whom only 1% to 2% are diagnosed today, according to Pfizer.